If ENHANCE had been positive, it would have allowed Merck and Schering-Plough to get a marketing claim for atherosclerosis from the Food and Drug Administration, as AstraZeneca's Crestor has.
While any net new job creations are positive, couple the declining number of new job creations with the increasing trend of unemployment claim filings and one can see a job market that is becoming more dubious than many were expecting at this stage of the economic recovery.